Last updated: July 11, 2026
Mitsubishi Tanabe Pharma Corporation (MTP) sued Aurobindo Pharma USA, Inc. in the District of Delaware over asserted IP covering an FDA-approved drug product in which Aurobindo sought to enter via an ANDA. The case is identified as 1:20-cv-03102. Public docket records provide the procedural posture and the core litigation timeline, while the merits analysis depends on the specific patents asserted, the claimed Orange Book listings, and the paragraph IV grounds alleged in the ANDA. Those patent-specific identifiers are not present in the provided input, so no accurate patent-by-patent infringement, validity, or enforceability analysis can be produced.
What is Mitsubishi Tanabe Pharma v. Aurobindo Pharma USA, 1:20-cv-03102?
Short answer: A federal Hatch-Waxman patent infringement suit in the District of Delaware brought by Mitsubishi Tanabe Pharma Corporation against Aurobindo Pharma USA, Inc. under 35 U.S.C. § 271(e)(2), tied to an ANDA entry plan. The docket number is 1:20-cv-03102.
Case caption
- Plaintiff: Mitsubishi Tanabe Pharma Corporation
- Defendant: Aurobindo Pharma USA, Inc.
- Court: U.S. District Court for the District of Delaware
- Docket: 1:20-cv-03102
What patents did Mitsubishi Tanabe assert against Aurobindo in 1:20-cv-03102?
Short answer: The specific asserted patent numbers and claims cannot be stated from the information provided. Patent-by-patent analysis requires the complaint’s asserted list and the asserted Orange Book mappings, neither of which appears in the input.
How to read the complaint’s patent map in Hatch-Waxman suits
In § 271(e)(2) ANDA cases, the complaint typically:
- Identifies the FDA NDA/Orange Book reference product.
- Lists the Orange Book patents asserted for infringement.
- Matches each asserted patent to an ANDA paragraph IV certification.
A litigation summary that links infringement contentions to claim language and product theory must start with those patent identifiers.
What is the procedural timeline of 1:20-cv-03102 (motions, hearings, rulings)?
Short answer: A full timeline requires docket events (dates and dispositions) that are not contained in the prompt. Without the docket event list, any statement about:
- scheduling order milestones,
- Markman dates,
- motion to dismiss outcomes,
- summary judgment rulings,
- claim construction determinations,
- trial/bench outcomes,
- or settlement terms,
would risk being inaccurate.
What procedural milestones usually matter in this type of case
For business and litigation planning, the key docket items normally include:
- Motion to dismiss (timeliness, standing, infringement pleading sufficiency).
- Claim construction (Markman) and resulting claim scope.
- Summary judgment on invalidity/enforceability if resolved.
- Trial scheduling or alternative resolution (stipulations, consent judgments).
- Any settlement terms that trigger a modified launch or dismissal.
Those dates and dispositions must be taken from the docket.
What is the Orange Book status of the drug at issue in 1:20-cv-03102?
Short answer: The Orange Book listings and their expiration dates cannot be identified from the supplied input.
What Orange Book data drives litigation exposure
The Orange Book record for the reference listed drug (RLD) typically supplies:
- Patent numbers and types (drug substance, drug product, method-of-use).
- Expiration dates and any regulatory exclusivities.
- Whether the listed patents appear to be method-of-use vs formulation vs product.
This drives:
- which patents are plausibly asserted in litigation,
- whether a generic launch is blocked by a still-in-force patent,
- and what carve-outs a settlement would address.
How strong is Mitsubishi Tanabe’s patent estate in this case?
Short answer: Patent strength cannot be scored from the provided input because the asserted patent portfolio is not specified.
Framework used for strength scoring in ANDA cases
Once asserted patents are known, an analyst would usually score strength using:
- claim breadth (especially method-of-use vs composition limitations),
- prior art landscape and obviousness vulnerability,
- prosecution history (estoppel and narrowing amendments),
- whether the patents have survived validity challenges in prior cases,
- and whether enforcement mechanisms (injunction posture) are available.
Without the patent numbers, no valid strength assessment can be made.
What are the infringement and validity issues likely to be in 1:20-cv-03102?
Short answer: The infringement and validity issues depend on the specific asserted claims and the ANDA product theory. The prompt does not include:
- the asserted claim types,
- the accused dosage form,
- the proposed bioequivalence pathway details,
- or the paragraph IV certification basis.
Typical issue clusters
In practice, Delaware ANDA cases commonly litigate:
- infringement of drug product claims (formulation/composition features),
- infringement of method-of-use claims (patient selection, dosing regimens, treatment indications),
- noninfringement tied to label differences or formulation design,
- invalidity for anticipation/obviousness under § 102/§ 103,
- indefiniteness under § 112,
- lack of enablement or written description.
But the correct cluster allocation is patent-claim dependent.
Did Aurobindo file counterclaims or launch-related defenses in 1:20-cv-03102?
Short answer: Counterclaims and defenses cannot be summarized without the docket filings and the answer/counterclaim content.
Common defenses in Hatch-Waxman ANDA suits
Typical defenses include:
- noninfringement,
- invalidity (anticipation, obviousness),
- unenforceability (inequitable conduct),
- lack of patent eligibility or indefiniteness,
- and procedural defenses (standing, failure to state a claim).
What settlement or consent judgment terms affected market entry?
Short answer: No settlement or consent judgment terms are available in the prompt. A launch-blocking effect cannot be described without:
- docket disposition (dismissal with/without prejudice, consent judgment),
- any stipulated injunction,
- and the settlement’s effective launch date, payment, or license terms.
What generic entry risks exist for Aurobindo after 1:20-cv-03102?
Short answer: Entry risk cannot be assessed because the case resolution status and patent list are missing.
Risk drivers that analysts use
Once asserted patents and case disposition are known, generic entry risk is assessed on:
- whether the remaining patents are still-in-force,
- whether the ANDA was dismissed or retained,
- whether the settlement includes a stipulated launch date,
- whether any other defendants are litigating overlapping patents,
- and whether regulatory exclusivities (if any) extend beyond patent expiry.
How does this case compare with other Hatch-Waxman litigations involving Mitsubishi Tanabe Pharma?
Short answer: A comparative analysis cannot be performed from the provided input. Comparison requires:
- other Mitsubishi Tanabe v. generic defendant cases,
- shared patent families or product pipelines,
- and outcomes that show repeating claim interpretation or settlement patterns.
Key Takeaways
- The District of Delaware case Mitsubishi Tanabe Pharma Corporation v. Aurobindo Pharma USA, Inc. (1:20-cv-03102) is a Hatch-Waxman ANDA-related patent infringement matter under 35 U.S.C. § 271(e)(2).
- A complete, accurate litigation summary and analysis must identify the asserted patent numbers/claims and the docket dispositions. Those inputs are not provided, so no reliable claim-level, validity-level, or resolution-level analysis can be produced from the prompt alone.
- Any business conclusion about exclusivity blocks, launch impact, or patent estate strength is contingent on the missing patent and docket details.
FAQs
-
What statute does Mitsubishi Tanabe use in ANDA patent suits like 1:20-cv-03102?
Typically 35 U.S.C. § 271(e)(2) for patent infringement based on ANDA paragraph IV certification, but the specific asserted counts must be taken from the complaint.
-
Does a filing in the District of Delaware usually include Markman claim construction?
Most Hatch-Waxman cases proceed to claim construction schedules, but the actual events for this docket require the case management order and docket entries.
-
Can paragraph IV certifications be dismissed without prejudice in these cases?
Dismissal posture depends on the court’s rulings and the parties’ settlement or procedural motions; that status is not provided.
-
How do method-of-use vs drug product patents affect infringement analysis?
Method-of-use claims hinge on patient treatment and label/dosing alignment; drug product claims hinge on formulation/composition features. The exact claim type in this case is unknown from the prompt.
-
What information is required to compute Aurobindo’s launch date risk from a settlement?
The settlement or consent judgment terms, any stipulated launch date, and the status of any remaining patents must be extracted from the docket.
References
- Docket entry reference: Mitsubishi Tanabe Pharma Corporation v. Aurobindo Pharma USA, Inc., 1:20-cv-03102 (D. Del.). (Not fully cited due to missing docket-text and patent-list details in the prompt.)
